284 related articles for article (PubMed ID: 20693846)
1. Myeloid-derived suppressor cells in human cancer.
Nagaraj S; Gabrilovich DI
Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
[TBL] [Abstract][Full Text] [Related]
2. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
Fujimura T; Mahnke K; Enk AH
J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of myeloid-derived suppressor cells.
Ugel S; Delpozzo F; Desantis G; Papalini F; Simonato F; Sonda N; Zilio S; Bronte V
Curr Opin Pharmacol; 2009 Aug; 9(4):470-81. PubMed ID: 19616475
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
[TBL] [Abstract][Full Text] [Related]
5. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
Ye XZ; Yu SC; Bian XW
J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
[TBL] [Abstract][Full Text] [Related]
6. Camouflage and sabotage: tumor escape from the immune system.
Poschke I; Mougiakakos D; Kiessling R
Cancer Immunol Immunother; 2011 Aug; 60(8):1161-71. PubMed ID: 21626032
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cell heterogeneity in human cancers.
Solito S; Marigo I; Pinton L; Damuzzo V; Mandruzzato S; Bronte V
Ann N Y Acad Sci; 2014 Jun; 1319():47-65. PubMed ID: 24965257
[TBL] [Abstract][Full Text] [Related]
8. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
[TBL] [Abstract][Full Text] [Related]
9. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
Lizée G; Radvanyi LG; Overwijk WW; Hwu P
Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
[TBL] [Abstract][Full Text] [Related]
10. On the armament and appearances of human myeloid-derived suppressor cells.
Poschke I; Kiessling R
Clin Immunol; 2012 Sep; 144(3):250-68. PubMed ID: 22858650
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
[TBL] [Abstract][Full Text] [Related]
12. Immune responses in hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
[TBL] [Abstract][Full Text] [Related]
13. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.
Lindau D; Gielen P; Kroesen M; Wesseling P; Adema GJ
Immunology; 2013 Feb; 138(2):105-15. PubMed ID: 23216602
[TBL] [Abstract][Full Text] [Related]
14. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
Tadmor T; Attias D; Polliack A
Br J Haematol; 2011 Jun; 153(5):557-67. PubMed ID: 21477210
[TBL] [Abstract][Full Text] [Related]
16. Derangement of immune responses by myeloid suppressor cells.
Serafini P; De Santo C; Marigo I; Cingarlini S; Dolcetti L; Gallina G; Zanovello P; Bronte V
Cancer Immunol Immunother; 2004 Feb; 53(2):64-72. PubMed ID: 14593498
[TBL] [Abstract][Full Text] [Related]
17. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
[TBL] [Abstract][Full Text] [Related]
18. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
[TBL] [Abstract][Full Text] [Related]
19. Role of tyrosine kinase inhibitors in tumor immunology.
Nishioka Y; Aono Y; Sone S
Immunotherapy; 2011 Jan; 3(1):107-16. PubMed ID: 21174561
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
Sinha P; Clements VK; Ostrand-Rosenberg S
Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
